Inspira Technologies OXY B.H.N. (IINN) Expected to Announce Quarterly Earnings on Wednesday

Posted by Micah Haroldson on Mar 30th, 2026

Inspira Technologies OXY B.H.N. (NASDAQ:IINN – Get Free Report) is projected to release its results before the market opens on Wednesday, April 1st. Analysts expect Inspira Technologies OXY B.H.N. to post earnings of ($0.20) per share and revenue of $0.20 million for the quarter.

Inspira Technologies OXY B.H.N. Stock Performance

Inspira Technologies OXY B.H.N. stock opened at $0.39 on Monday. Inspira Technologies OXY B.H.N. has a 52-week low of $0.34 and a 52-week high of $1.65. The company has a quick ratio of 1.30, a current ratio of 1.56 and a debt-to-equity ratio of 0.08. The firm’s fifty day moving average is $0.63 and its 200 day moving average is $0.91.

Hedge Funds Weigh In On Inspira Technologies OXY B.H.N.

An institutional investor recently bought a new position in Inspira Technologies OXY B.H.N. stock. Kestra Advisory Services LLC bought a new stake in shares of Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 78,824 shares of the company’s stock, valued at approximately $71,000. 12.72% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Inspira Technologies OXY B.H.N. in a report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $2.00.

View Our Latest Research Report on Inspira Technologies OXY B.H.N.

Inspira Technologies OXY B.H.N. Company Profile

(Get Free Report)

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.